… These toxicities usually develop within the first few weeks to months after treatment … –PD-1
immunotherapy, we performed transcriptomic analysis of Tregs from individuals with kidney, …

… Akt/mTOR pathway may be a promising therapeutic target for … to the progression of OSCC
cells and the tumoricidal efficacy … revealed that blocking the PD-1/PD-L1 pathway reduced the …

… Apart from programmed cell death protein 1/ligand 1 (PD-1/L1) and cytotoxic T-… , targeting
novel negative immune checkpoints in RCC has yet to demonstrate convincing efficacy in early …

… limiting metabolic and immunosuppressant toxicities. In addition … PD-1 expression, a known
factor in impairing T cell signaling… for immunosuppression in renal transplant patients are 16–…

… One retrospective study included 6 kidney transplant patients, who did not fit our inclusion
… into the role of mTOR inhibitors in uncoupling the efficacy and toxicity of PD-1 inhibition, but …

… Additionally, when effector T cells are activated, PD-1 signaling inhibits glycolysis and induces
… level of the PI3K-AKT-mTOR axis is significant to the efficiency of mTOR-related therapy. …

… inhibit the binding of PD-1 to PD-L1/2, thereby blocking the … us to analyze ~700 immune-related
target gene profiles. This study … and efficacy of nivolumab for all types of cancer in kidney …

… the programmed cell death 1 (PD-1)/programmed cell death … 27 cases were evaluable for
efficacy. The overall response … ICI-induced hematological toxicities, myasthenia gravis, and …

… T cell efficacy and to decrease treatment-associated toxicity. The … targeting PD-1, PD-L1,
CTLA-4, and 4-1BB (Table 2). … receptor tyrosine kinase inhibitor used for the treatment of renal …

… chronic kidney disease, CCR6 − CXCR3 − CXCR5 + PD-1 + … cell renal carcinoma through
activating PI3K/AKT/mTOR … could result in decreased ICB effectiveness. Promoting tolerance …